References
- Adams G.E. The clinical relevance of tumour hypoxia. European Journal of Cancer 1990; 26: 420–421
- Algire G., Legallais F.Y., Anderson B.F. Vascular reactions of normal and malignant tissues in vivo. IV. The effect of peripheral hypotension on transplanted tumours. Journal of the National Cancer Institute 1951; 12: 399–421
- Baba T., Aoki, Kuroiwa T., Taniguchi S. Some cardiotonics enhance the effectiveness of angiotensin II-induced hypertension cancer chemotherapy in mice. Japanese Journal of Cancer Research 1986; 77: 432–435
- Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissueisolated and subcutaneous tumours: implications for therapy. Cancer Research 1990; 50: 4478–4484
- Brown, J.M. Exploitation of bioreductive agents with vasoactive drugs. Proceedings of the 8th International Congress of Radiation Research Proceedings of the 8th International Congress of Radiation ResearchEdinburghUKE.M. Fielden, et al. Taylor & Francis, London 1987; 719–724
- Chaplin, D.J. Hypoxia-targeted chemotherapy: a role for vasoactive drugs. Proceedings of the 8th International Congress of Radiation Research Proceedings of the 8th International Congress of Radiation ResearchEdinburghUKE.M. Fielden, et al. Taylor & Francis, London 1987; 731–736
- Hirst D.G., Wood P.J. The control of tumour blood flow for therapeutic benefit. Scientific Basis of Modern Radiotherapy. BIR, London 1989; 19: 76–80
- Horsman M.R., Christensen K.L., Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. International Journal of Hyperthermia 1989; 5: 123–126
- Jain R.K. Determinants of tumour blood flow: a review. Cancer Research 1988; 48: 2641–2658
- Jirtle R.L. Chemical modification of tumour blood flow. International Journal of Hyperthermia 1988; 4: 355–371
- Sapirstein L.A. Regional blood flow by functional distribution of indicators. American Journal of Physiology 1958; 193: 161–168
- Stratford, I.J., Godden, J., Howells, N., Embling, P., Adams, G.E. Manipulation of tumor oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours. Proceedings of the 8th International Congress of Radiation Research Proceedings of the 8th International Congress of Radiation ResearchEdinburghUKE.M. Fielden, et al. Taylor & Francis, London 1987; 737–742
- Stratford I.J., Stephens M.A. The differential cytotoxicity of bioreductive agents determined in vitro by the MTT assay. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 973–976
- Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W. A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1239–1242